This document summarizes presentations from the 2007 Transcatheter Cardiovascular Therapeutics conference. Key findings include:
- The ARMYDA-4 trial found that a 600mg clopidogrel loading dose prior to PCI in patients on chronic clopidogrel therapy reduced the risk of death, MI, or TVR at 30 days compared to placebo.
- The HORIZONS AMI trial found that using bivalirudin monotherapy during PCI for AMI reduced major bleeding at 30 days compared to unfractionated heparin plus a GP IIb/IIIa inhibitor, with similar rates of net adverse clinical events.
- Data from the EVENT registry showed declining rates of bleeding complications and stent
Ponencia realizada por el Dr. Montalescot y presentada por el Dr. José Antonio Gómez Hospital en la Reunión EuroIMAT 2020, celebrada en Barcelona (20 y 21 de febrero de 2020).
Novedades en el manejo del paciente con FA: actualización tras AHA 2016
22/11/2016 19:30h Casa del Corazón, Madrid
http://manejofa.secardiologia.es
#manejoFA
Seguimiento de pacientes con FA y SCA tras intervención coronaria percutánea. Evidencia con ACOD
Dr. Marcelo Sanmartín Fernández, Hospital Universitario Ramón y Cajal (Madrid)
Ponencia realizada por el Dr. Montalescot y presentada por el Dr. José Antonio Gómez Hospital en la Reunión EuroIMAT 2020, celebrada en Barcelona (20 y 21 de febrero de 2020).
Novedades en el manejo del paciente con FA: actualización tras AHA 2016
22/11/2016 19:30h Casa del Corazón, Madrid
http://manejofa.secardiologia.es
#manejoFA
Seguimiento de pacientes con FA y SCA tras intervención coronaria percutánea. Evidencia con ACOD
Dr. Marcelo Sanmartín Fernández, Hospital Universitario Ramón y Cajal (Madrid)
This presentation discusses the latest evidence for blood transfusion triggers in the intensive care unit of various clinical condition including severe sepsis, GI bleed, post surgical cases, and post cardiac surgery among other cnditions
Heart Disease & Chest Pain Treatment At NT Cardiovascular Center Georgiamelvillejackson
http://www.ntcardiovascularcenter.com NT Cardiovascular Center providing latest cutting edge and comprehensive technology for heart disease, chest pain treatments, congestive heart failure, coronary artery disease monitoring, or any critical heart condition.
XXVII Reunión anual de la sección de Hemodinámica y Cardiología Intervencionista
16 y 17 de junio de 2016 León
http://secardiologia.es/xxvii-reunion-anual-de-la-seccion-de-hemodinamica-y-cardiologia-intervencionista
Novedades en farmacología en intervencionismo
Antonio Fernández Ortiz (Hosp. Clínico San Carlos. Madrid)
Antiplatelet therapy there is a gap between guidelines and implementationA.Salam Sharif
platelets play an important role in cardiovascular diseases, the final event leading to ACS is a spontaneous atherosclerotic plaques which initiates a platelet response with platelet adhesion to vascular wall with activation and agregation and finally clot formation with clinical sequences od CV deaths, MI and myocardial ischemia and arrhythmias, so atiplatelet therapy is crucial in treatment of ACS, in the topic I review the traditional agents and new agents , focusing on guidelines and real world of their cinical uses .
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
1. ACS Critical Pathways 2007 Teleconferences This activity is supported by an educational grant from the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. This activity is co-provided by the Network for Continuing Medical Education and EduPro Resources LLC. October 31, 2007
2.
3. The Network for Continuing Medical Education and EduPro Resources LLC require that CME/CNE faculty disclose, during the planning of an activity, the existence of any personal financial or other relationships they or their spouses/partners have with the commercial supporter of the activity or with the manufacturer of any commercial product or service discussed in the activity. Disclosure Statement
8. Percentage 7 8 P =.96 Patti G, et al. Presented at: Transcatheter Cardiovascular Therapeutics 2007; October 20-25, 2007; Washington, DC. ARMYDA-4: Composite Primary End Point of 30-day Death, MI, TVR 0 3 6 9 12 Placebo 600 mg clopidogrel reload
9. Patti G, et al. Presented at: Transcatheter Cardiovascular Therapeutics 2007; October 20-25, 2007; Washington, DC. 7 8 Percentage 600 mg clopidogrel reload Placebo ARMYDA-4: Individual Events at 30 Days 0 2 4 6 8 10 Death MI TVR
10. Patti G, et al. Presented at: Transcatheter Cardiovascular Therapeutics 2007; October 20-25, 2007; Washington, DC. ARMYDA-4: Bleeding Rates 600 mg clopidogrel reload Placebo 4 4 0 0 Percentage 0 2 4 6 Major bleeding Minor bleeding
11.
12. ARMYDA-5: Results PRUs = platelet reactivity units. Di Sciascio G, et al. Presented at: Transcatheter Cardiovascular Therapeutics 2007; October 20-25, 2007; Washington, DC. NS 5% 4% Minor bleeding .04 .005 272 PRUs 245 PRUs 241 PRUs 186 PRUs Platelet reactivity at PCI At 2 hours: .56 11% 8% Death, MI, or TVR at 30 days P Value Cath-lab treatment Pretreatment
13.
14.
15. HORIZONS AMI: Study Drugs a 97.7% and 7.5% during PCI; b For giant thrombus or refractory no reflow after PCI. CCL = cardiac catheterization laboratory. Stone GW, et al. Presented at: Transcatheter Cardiovascular Therapeutics 2007; October 20-25, 2007; Washington, DC. UFH + GP IIb/IIIa (N=1802) Bivalirudin (N=1800) UFH prerandomization 65.6% 65.6% Antithrombin in CCL - UFH 98.9% 4.1% - Bivalirudin 0.4% 96.9% - Peak ACT 264 [228, 320] 357 [300, 402] GP IIb/IIIa in CCL 94.5% a 7.2% a - Bail-out per protocol b - 4.4% - Abciximab 49.9% 4.0% - Eptifibatide 44.4% 3.1% - Tirofiban 0.2% 0.1%
16.
17. 30-day Net Adverse Clinical Events Number at risk Bivalirudin 1800 1660 1633 1626 1620 1607 1544 Heparin + GP IIb/IIIa 1802 1635 1591 1578 1569 1552 1482 Primary End Point Net adverse clinical events (%) Time in Days 12.2% 9.3% HR [95%CI] = 0.75 [0.62, 0.92] P =.006 Heparin + GP IIb/IIIa inhibitor (n=1802) Bivalirudin monotherapy (n=1800) Stone GW, et al. Presented at: Transcatheter Cardiovascular Therapeutics 2007; October 20-25, 2007; Washington, DC.
18. 30-day Major Bleeding (non-CABG) Number at risk Bivalirudin 1800 1697 1675 1668 1664 1653 1590 Heparin + GP IIb/IIIa 1802 1651 1617 1606 1598 1581 1511 Primary End Point Major bleeding (%) Time in Days 8.4% 5.0% HR [95%CI] = 0.59 [0.45, 0.76] P <.0001 Stone GW, et al. Presented at: Transcatheter Cardiovascular Therapeutics 2007; October 20-25, 2007; Washington, DC. Heparin + GP IIb/IIIa inhibitor (n=1802) Bivalirudin monotherapy (n=1800)
19. 30-day Bleeding End Points a Primary end point; b life threatening. Stone GW, et al. Presented at: Transcatheter Cardiovascular Therapeutics 2007; October 20-25, 2007; Washington, DC. UFH + GP IIb/IIIa (N=1802) Bivalirudin (N=1800) P Value Protocol Major, non-CABG a 8.3% 4.9% <.0001 Protocol Major, All 10.8% 6.8% <.0001 Protocol Minor 15.4% 8.6% <.0001 Blood transfusion 3.5% 2.1% .01 TIMI Major 5.0% 3.1% .003 TIMI Minor 4.6% 2.8% .008 TIMI Major or Minor 9.6% 5.9% <.0001 GUSTO LT b or Severe 0.6% 0.4% .65 GUSTO Moderate 5.0% 3.1% .003 GUSTO LT or Sev or Mod 5.6% 3.5% .003
20. 30-day MACE Components a a CEC adjudicated. Stone GW, et al. Presented at: Transcatheter Cardiovascular Therapeutics 2007; October 20-25, 2007; Washington, DC. UFH + GP IIb/IIIa (N=1802) Bivalirudin (N=1800) P Value Death 3.1% 2.1% .058 - Cardiac 2.9% 1.8% .035 - Noncardiac 0.2% 0.3% .75 Reinfarction 1.8% 1.8% .90 - Q wave 1.2% 1.4% .66 - Non – Q wave 0.7% 0.4% .50 Ischemic TVR 1.9% 2.6% .18 - Ischemic TLR 1.8% 2.5% .14 - Ischemic remote TVR 0.3% 0.3% 1.0 Stroke 0.6% 0.7% .69
21. SPIRIT III: MACE Through 365 Days MACE = cardiac death, MI, or ischemia-driven TLR. Stone GW, et al. Presented at: Transcatheter Cardiovascular Therapeutics 2007; October 20-25, 2007; Washington, DC. 0 3 6 12 9 MACE (%) 0 90 180 270 365 Days 9.9% 5.8% TAXUS XIENCE HR = 0.57 [0.36 – 0.90 ] P logrank = .01 Number at risk XIENCE 669 651 642 626 614 TAXUS 332 312 309 292 287
22. Endeavor IV: Primary End Point Result at 9 Months Leon MB, et al. Presented at: Transcatheter Cardiovascular Therapeutics 2007; October 20-25, 2007; Washington, DC. P for Noninferiority <.001 ∆ = 3.8% 6.6% 7.2% Endeavor (n=50/758) Taxus (n=54/759) TVF Rate Target Vessel Failure
23. a Day 83, 145, 171. Leon MB, et al. Presented at: Transcatheter Cardiovascular Therapeutics 2007; October 20-25, 2007; Washington, DC. Endeavor IV: Clinical Events at 12 Months .267 9.4 (70 7.7 (58) TVF – % (#) 1.000 6.6 (49) 6.5 (49) MACE – % (#) .753 6.7 (50) 6.3 (47) TVR – % (#) .085 4.2 (31) 2.5 (19) TVR (non-TL) – % (#) .228 3.2 (24) 4.5 (34) TLR – % (#) .250 0 0.4 a (3) 31-360 days .625 0.1 (1) 0.4 (3) 0-30 days .124 0.1 (1) 0.8 (6) Stent Thrombosis (all) – % (#) .260 3.1 (23) 2.1 (16) Death (cardiac) + MI (all) – % (#) .131 2.4 (18) 1.3 (10) Non – Q wave 1.000 0.1 (1) 0.3 (2) Q Wave .208 2.6 (19) 1.6 (12) MI (all) – % (#) 1.000 0.5 (4) 0.5 (4) Cardiac 1.000 1.1 (8) 1.1 (8) Death (all) – % (#) P Value Taxus n=741 Endeavor n=749
24. EVENT Registry: Bleeding Complications Kleiman N, et al. Presented at: Transcatheter Cardiovascular Therapeutics 2007; October 20-25, 2007; Washington, DC. 0.6 0.0% 2.0% 4.0% 6.0% TIMI Major 0.2 0.2 1.0 0.8 0.5 3.5 2.0 1.8 5.2 4.1 3.4 TIMI Minor Transfusion Any bleed or transfusion Not mutually exclusive WAVE 2 WAVE 1 WAVE 3
25. EVENT Registry: Adjudicated Stent Thrombosis From Procedure to 1 Year Follow-up Kleiman N, et al. Presented at: Transcatheter Cardiovascular Therapeutics 2007; October 20-25, 2007; Washington, DC. 2.2% 0% WAVE 2 WAVE 1 WAVE 3 P = .046 P = .027 (Logistic regression) In Hospital 6 Months 12 Months Wave 2 is ARC Probable ; Wave 3 is ARC Definite or Probable Wave 1 to Wave 3 1.1 0.8 0.9 1.9 1.0 1.2 (Log rank) 0.4 0.2 0.1
26. Carlsson J, et al. Presented at: Transcatheter Cardiovascular Therapeutics 2007; October 20-25, 2007; Washington, DC. SCAAR: Adjusted Death/MI Total Cohort BMS 10049 9529 9343 8112 6742 5265 3486 1892 5 DES 6523 6222 6069 4428 2947 1868 908 322 0 BMS 9434 8424 8223 6896 5431 4012 2433 1285 2 DES 6165 5673 5512 3792 2508 1525 780 287 0 0.25 0.20 0.15 0.10 0.05 0.00 0 1 2 3 4 Cumulative risk of death or MI RR: 1.03 (0.93, 1.15) BMS DES On label use N=17,664 Time (years) 0.25 0.20 0.15 0.10 0.05 0.00 0 1 2 3 4 Cumulative risk of death or MI RR: 0.96 (0.88, 1.06) BMS DES Off label use N=16,866 Time (years)
27. Carlsson J, et al. Presented at: Transcatheter Cardiovascular Therapeutics 2007; October 20-25, 2007; Washington, DC. SCAAR: Restenosis at Clinically Driven Re-angiography BMS 3987 3794 3698 3079 2188 1140 50 0 0 DES 3235 3142 3080 2354 1389 630 21 0 0 BMS 3586 3291 3202 2649 1812 909 24 0 0 DES 2158 2034 1966 1407 846 339 11 0 0 0.10 0.08 0.06 0.04 0.02 0.00 0 1 2 3 4 Cumulative risk of death or MI RR: 0.39 (0.3, 0.51) BMS DES On label use N=12,186 Time (years) 0.10 0.08 0.06 0.04 0.02 0.00 0 1 2 3 4 Cumulative risk of death or MI RR: 0.66 (0.5, 0.88) BMS DES Off label use N=9,155 Time (years) RRR 60% ARR 4% RRR 40% ARR 2.5%
28. NY State Database and STENT Registry Brodie BR, et al. Presented at: Transcatheter Cardiovascular Therapeutics 2007; October 20-25, 2007; Washington, DC. Clinical Outcomes of DES vs BMS in the New York Database 2.98 ( P <.001) 2.23 ( P <.001) 1.17 1.17 Adjusted HR Second analysis of significant predictors of mortality (n=4,983) 2.30 1.85 1.19 1.19 Adjusted HR for BMS/DES 2.17 1.77 1.25 1.26 Unadjusted HR for BMS/DES 9.4% 6.1% 7.8% 4.8% DES (n=6,384) 16.6% 13.5% 9.2% 5.6% BMS (n=7,834) Rate of subsequent TVR Rate of subsequent TLR MI or death Mortality 2-year data
29. NY State Database and STENT Registry Brodie BR, et al. Presented at: Transcatheter Cardiovascular Therapeutics 2007; October 20-25, 2007; Washington, DC. Clinical Outcomes of DES vs BMS in the STENT Registry 35.4% 2% Year 1-2 19% 9% 30 days to 1 year 45.6% 57.7% Timing of stent thrombosis <30 days 16.1% 24.7% MACE 9.1% 16% Death or MI 8.8% 11.9% TVR 4.1% 6.7% MI 5.7% 11% Death DES (n=5,996) BMS (n=1,359) 2-year data
32. Progress Checklist: Immediate Goals Assemble team and set up meeting of working group Develop draft pathways Circulate pathways to all cardiology, ED, and CV nursing staff for comments Circulate discharge plan and other tools to all cardiology, ED, and CV nursing staff for comments
33. Progress Checklist: Short-term Goals/Activities Finalize critical pathways Launch critical pathways Circulate memo Grand rounds/conference: Cardiology/IM Grand rounds/conference: Emergency Department Grand rounds/conference: Nursing
34. Progress Checklist: Long-term Goals/Activities Monitor data: which registry? NRMI AHA Get With The Guidelines ACC National Cardiovascular Data Registry CRUSADE GRACE REACH Other
36. Concluding Remarks Gregg C. Fonarow, MD Next Program Christopher P. Cannon, MD Wednesday, November 14, 2007 12:00 Noon Eastern Time (9:00 AM Pacific Time) Report From the American Heart Association (AHA) Scientific Sessions 2007